title: [Improvement of quality of life (QOL) and life prolongation by CPT-11 + adriamycin (ADM) therapy: report of 4 cases of non-Hodgkin's lymphoma refractory to conventional chemotherapies].
abstract: CPT-11 + ADM therapy (CPT-11 40 mg/body x 2 days; Day 1 & 2, combined with ADM 20 to 60 mg/body x 1 day; Day 3) was given to four patients with relapsed and advanced non-Hodgkin's lymphoma, which was refractory to conventional chemotherapies. The symptoms of the patients at the beginning of CPT-11 + ADM therapy were fever (in two cases), dyspnea due to pleural effusion (in two), severe backache (in one), and jaundice with splenomegaly (in one). Their Karnofsky performance scales were 20 or 30%. Soon after the initiation of CPT-11 + ADM therapy, their clinical conditions improved dramatically, and they obtained a partial remission lasting 3.5 to 9 months. During the period of controlling lymphomas by this therapy, all patients had some time at home for 2 to 8 months. The adverse effects were vomiting, diarrhea, neutropenia and thrombocytopenia, but no lethal infection or hemorrhage was seen. We conclude that CPT-11 + ADM therapy is very useful for improvement of QOL and life prolongation of patients with non-Hodgkin's lymphoma, which is refractory to conventional chemotherapies and is even disseminated.
authors.affiliation: Division of Hematology and Chemotherapy, Chiba Cancer Center Hospital.
authors.forename: C
authors.initials: C
authors.lastname: Sakai
authors.forename: T
authors.initials: T
authors.lastname: Saotome
authors.forename: A
authors.initials: A
authors.lastname: Takeshita
authors.forename: C
authors.initials: C
authors.lastname: Nakaseko
authors.forename: K
authors.initials: K
authors.lastname: Kumagai
authors.forename: T
authors.initials: T
authors.lastname: Takagi
mesh_terms: D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002166:Camptothecin / Q000008:administration & dosage / Q000031:analogs & derivatives; D004317:Doxorubicin / Q000008:administration & dosage; D004334:Drug Administration Schedule; D006801:Humans; D000077146:Irinotecan; D017567:Karnofsky Performance Status; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy* / Q000534:rehabilitation; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D011788:Quality of Life
chemical_list: D000077146:Irinotecan; D004317:Doxorubicin; D002166:Camptothecin